FibroBiologics, Inc.
(NASDAQ: FBLG)
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.
0.256
-0.004
(-1.54%)
Range
0.250 - 0.262
(4.80%)
Open
0.255
Previous Close
0.260
Bid Price
-
Bid Volume
-
Ask Price
-
Ask Volume
-
Volume
864,812
Value
-
Remark
Delayed prices. Updated at 06 Dec 2025 02:07.
Data powered by
View All Events
Loading Chart...
Please login to view stock data and analysis
